about
Clinical utility of nivolumab in the treatment of advanced melanomaRegulation of Natural Killer Cell Function by STAT3Immunotherapy of Ovarian Cancer: The Role of Checkpoint InhibitorsStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyHarnessing the power of Vδ2 cells in cancer immunotherapyPD-1 and its ligands are important immune checkpoints in cancerNivolumab in melanoma: latest evidence and clinical potentialRegulation of T-cell Tolerance by Lymphatic Endothelial Cells.Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis.Vitamin D increases programmed death receptor-1 expression in Crohn's disease.PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinomaImmune checkpoint inhibitors in clinical trialsCutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patientsCellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma.Opportunities in immunotherapy of ovarian cancer.PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature.PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression.Acute Hyperglycemia Associated with Anti-Cancer Medication.Checkpoint inhibitors in immunotherapy of ovarian cancer.The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.Prohibitin - At the crossroads of obesity-linked diabetes and cancer.Five Layers of Receptor Signaling in γδ T-Cell Differentiation and ActivationThe immune system and cancer evasion strategies: therapeutic concepts.Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis.Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Are there, or shall we discover, biomarkers to guide PD-1 inhibition?Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?Immunotherapy in pancreatic cancer treatment: a new frontier.Targeting the programmed cell death-1 pathway in rheumatoid arthritis.Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis.Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
P2860
Q26751268-9ECCB128-E899-49EB-9F42-30183BA7A535Q26752551-6C78B8BA-58C4-4F56-BA05-0171DEBBA036Q26799812-55760F5E-7389-41A2-BA2A-E4644BABF7FAQ26823515-A9031AC0-EC5E-45F1-B79B-B52641083AA7Q27027547-77941A7C-087D-423C-883F-8452E5E02AEBQ28069485-23B98F93-EF2D-4E42-B5C3-8B14C05960D2Q28258598-593BD44C-B30E-4C99-8B49-5E1C60420E60Q30300970-D5EF70F5-C400-42E9-9B41-37254BF78382Q33419344-14981835-A7DF-4430-9BE1-C783E0C6FEC5Q33648411-DC78BD6D-6FD8-4BE0-90AA-F6D790005456Q33648598-54EA8C5A-17E1-4A88-B5F5-994A6D061179Q33889053-AF106D32-B7F5-45D2-9462-609C1ECBC4D4Q34309394-21DF13C3-B3DA-4E8C-A7B4-1829B836CF84Q35815759-0522C684-FECF-4196-B3BF-5285A9880CD6Q36141581-D0C17E4A-900A-4EC0-BA19-34F56DAF7009Q36356608-9AB93D03-926E-4EC6-BE34-833FA17FEBD3Q36757025-96E32D31-ECF0-493B-9B46-9B99A1C438F7Q36855245-793C2D78-3BF9-4072-9EDB-34C3B266065AQ37429917-CBB66D5F-0239-43BB-BA45-8F40B6725F4DQ37562989-5EA87B50-F1ED-46BC-AE8C-9AC931A56DAAQ37662425-FB65C58B-96FC-4ED2-867F-F056C18D658BQ37723241-E0757AB5-8F3B-4FB7-9458-A5512F4132E9Q38269568-B07F6EF7-7872-4BEC-A5D6-E60FFCBCEC92Q38285859-DECF781A-7EBC-4A95-814C-3DB905C55489Q38288384-1773AAEB-F7C6-4553-A22D-BFC3C9A39510Q38352469-C0AC5292-DF55-416D-949B-EA0FF1090CE2Q38691172-10A6EE2D-21FC-4425-AC09-66106AC409C2Q38695393-C6FE299F-B5A3-487B-A0E9-62F9FE15CDCBQ38696133-EE5AE019-CFD1-47CA-A56A-0034B84FFE87Q38720431-B74A60F5-E34F-4D35-B3CE-6507941F835BQ38743088-231AB639-9C24-4D07-B516-442B6B70C413Q38806038-82FF5054-0417-4FA1-9E70-BE76CF9B759DQ38838639-7F39B34C-3EC3-4956-947B-D46864906544Q38887303-59ED1742-DFB4-415D-A87F-9A040A985768Q38963228-28457CCE-7D94-41BA-BA48-FE5A4467F8DFQ39175499-93AC0BF5-341D-45F6-9553-BEB6BEF6D88BQ39344907-2DD22090-64B0-413E-A411-BC791366534CQ39413389-7208BC07-8830-4F7F-A54B-66B361CEA286Q39965259-C22EA7C2-4AC8-47C8-9983-70F4FF7A2003Q40517920-FAA59FA6-60AA-49AA-BE5B-9C4C62A1B05D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Programmed death-1 pathway in cancer and autoimmunity.
@en
type
label
Programmed death-1 pathway in cancer and autoimmunity.
@en
prefLabel
Programmed death-1 pathway in cancer and autoimmunity.
@en
P2093
P1433
P1476
Programmed death-1 pathway in cancer and autoimmunity
@en
P2093
Ariel Pedoeem
Inbar Azoulay-Alfaguter
Marianne Strazza
P304
P356
10.1016/J.CLIM.2014.04.010
P577
2014-04-26T00:00:00Z